Trials / Completed
CompletedNCT01433523
House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma
Efficacy of ALK House Dust Mite Allergy Immunotherapy Tablet in Subjects With House Dust Mite Induced Asthma. The MITRA Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 834 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to investigate if treatment with house dust mite allergen immunotherapy tablet can reduce the risk of asthma exacerbation in subjects with house dust mite induced asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALK HDM AIT Placebo | Oral lyophilisate, Placebo, to be administered sublingually once daily |
| DRUG | ALK HDM AIT 6 DU | Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months. |
| DRUG | ALK HDM AIT 12 DU | Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months. |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2013-04-01
- Completion
- 2014-02-01
- First posted
- 2011-09-14
- Last updated
- 2017-01-30
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01433523. Inclusion in this directory is not an endorsement.